News

TB R&D Weekly Update: Podcast Interview with Anne Lenaerts

14 Feb 2011
by Working Group
Front Lines of TB R&D TB Drug Development TB R&D Spotlight Interviews WGND Podcast Series
animal models innovations publications r&d

[wpaudio url=”/blog/media/podcasts/Anne_Lenaerts_Interview_edited-norm.mp3″ text=”Anne Lenaerts Interview” dl=”0″]

Listen to Anne Lenaerts Podcast


Summary: Dr. Anne Lenaerts is an associate professor at Colorado State University”s College of Veterinary Medicine and Biomedical Sciences in the Department of Microbiology, Immunology and Pathology. The WGND had the opportunity to talk with Dr. Lenaerts on a recent article published ahead of print in the Antimicrobial Agents and Chemotherapy journal in December 2010. In the interview, Dr. Lenaerts provides an overview of her present research and the article, key recommendations for use of mouse models for testing TB drugs and the issue of relapse studies.

Additional TB R&D News:

REVIEW: The challenge of new drug discovery for tuberculosis

Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies

Progress in tuberculosis vaccine research

Race against time to develop new antibiotics

S. Korean Biotech Company Decodes Antibiotic Resistant Superbug form

More News
22 Jul 2024

With NIH Funding, A New Consortium Aims to Improve TB Treatment

The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024

WHO Released Its Updated Bacterial Priority Pathogens List

On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024

Most Robust TB Drug Pipeline in History

For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...